Black Titan Corporation

Titan did not report quarterly revenue, EPS, or gross margin figures on the call, and management said the relevance of prior operating results is diminished because the company has transitioned back to a development-stage company. On the strategic and funding side, management said it completed a public offering two weeks earlier, and that NIDA awarded approximately $8.7 million over 2 years for nalmefene development, with approximately $6.3 million remaining available after IND acceptance. Forward-looking milestones include JT-09 proof-of-concept data in the second quarter of 2021 and a nalmefene IND filing in the first half of 2021.

Marc Rubin emphasized that Titan has reset itself into a development-stage company and that the restructuring is intended to position the company for future growth while substantially lowering fixed operating costs. He framed JT-09 and nalmefene as the company’s two core assets and highlighted the ProNeura platform as the basis for both near- and long-term value creation. His tone was cautious but constructive, with repeated references to upcoming milestones and updates.

The call did not include a detailed CFO financial review, but management highlighted several funding and program economics points. Titan completed a public offering two weeks earlier, and the nalmefene program is supported by an approximately $8.7 million NIDA grant over 2 years, with approximately $6.3 million remaining once the IND is accepted. Management also said the restructuring should substantially reduce fixed operating costs and that NIDA approved reallocating previously approved funds to support additional nonclinical work.

There was no analyst Q&A segment in the transcript. Management instead focused on explaining the programs and the regulatory path: FDA advised that nalmefene should follow a 505(b)(1) pathway because of limited safety data for a long-acting formulation, and the company said it will conduct additional nonclinical studies and extend an ongoing study to meet IND requirements. For JT-09, management said it is working toward proof-of-concept in chronic pruritus and would then move to IND-enabling safety and pharmacology studies if successful.